• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should FDA Approval Require Action From AbbVie (ABBV) Investors?

    Simply Wall St·09/28/2026 22:12:44
    Listen to the news
    • AbbVie reported that the FDA approved JUVMO, or tavapadon, as the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease, supported by long term TEMPO trial data and multiple tablet strengths for flexible dosing.
    • The approval adds a differentiated Parkinson's therapy to AbbVie's growing neuroscience franchise. Management already positions this franchise as a key pillar for replacing revenue from ageing blockbusters.
    • We will now look at how AbbVie’s investment narrative could shift as JUVMO’s new D1/D5 mechanism enters the Parkinson’s market.
    Capture how AbbVie’s neuroscience momentum fits into a broader healthcare opportunity set by scanning a hand picked group of 37 healthcare AI stocks.

    AbbVie Investment Narrative Recap

    Owning AbbVie is really a call on its ability to keep replacing ageing blockbusters with new franchises in immunology, neuroscience and oncology while managing debt, pricing pressure and patent expirations. The JUVMO approval feeds directly into that story, but the more immediate swing factor still looks like execution on Skyrizi and Rinvoq guidance, as well as broader earnings delivery after Humira.

    The biggest near term operational risk remains pricing and competitive pressure on key therapies, combined with high leverage and a dividend that current earnings do not fully cover. JUVMO does not change that quickly. It adds another future contributor, while the short term focus stays on margin resilience, debt service, and how far newer products can offset erosion elsewhere.

    The clearest related update is AbbVie’s broader neuroscience momentum, where management has pointed to higher 2026 revenue guidance supported by Vraylar and Vyalev. JUVMO plugs into that same segment. In practice, this means watching whether this cluster of neurologic therapies can mature into a material earnings pillar rather than a handful of niche assets.

    New real world Vraylar data in major depressive disorder and bipolar I disorder shows AbbVie still working to extend and defend that franchise. For shareholders, that kind of lifecycle work, combined with JUVMO’s new D1/D5 mechanism, shapes a practical question: can the neuroscience portfolio grow fast enough, and long enough, to counter patent risk, oncology pressure and drug price reform over the next few years.

    AbbVie’s current analyst storyline points to revenues of US$81.5b and earnings of US$24.3b by 2029, built on a projected 8.2% yearly increase in sales and a rise in profit from US$6.3b today. This implies an earnings uplift of about US$18b over that period.

    Uncover why AbbVie's fair value indicates a 5% potential upside to its current price that could narrow quickly.

    NYSE:ABBV 1-Year Stock Price Chart
    NYSE:ABBV 1-Year Stock Price Chart

    Exploring Other Perspectives

    The Simply Wall St Community contributes three fair value views for AbbVie, ranging from about US$279 to US$447 per share. That is a wide gap. Before the JUVMO, EPKINLY and RINVOQ updates, members were already divided on the potential upside. With patent risk, drug price reform and pipeline execution also in play, it becomes important to compare several viewpoints.

    Explore 2 other AbbVie fair value estimates, including one that suggests as much as 68% upside from the current price!

    Reach Your Own Conclusion

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking for more AbbVie style investment ideas?

    If AbbVie has sharpened your focus on quality healthcare exposure, it can help to widen the lens and compare it with other opportunities that fit different risk and income profiles.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.